Article
Deloitte China assists listing of ImmuneOnco on SEHK
2nd pre-revenue biotech listing assisted by Deloitte in Hong Kong this year
Publish date: 5 September 2023
Deloitte China supported the listing of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (ImmuneOnco, stock ticker: 01541.HK) on the Stock Exchange of Hong Kong (SEHK) on 5 September 2023. This is the 2nd pre-revenue biotech listing we have assisted to completion in Hong Kong this year. Since SEHK's launch of the listing regime for pre-revenue biotech companies, Deloitte China has been a leader in this market segment by funds raised and the market capitalisation of the pre-revenue biotech companies at time of listing.
ImmuneOnco offered 17.2 million shares at HKD18.6 per share, raising HKD320 million.
Deloitte China's ImmuneOnco IPO engagement team and the management and working team of ImmuneOnco attend the listing ceremony held at Hong Kong Stock Exchange: (top photo from left) Bobby Yu, Deloitte China's Eastern Region Offering Services partner, CMSG; Bobo Leung, A&A partner; Dr. Tian Wenzhi, ImmuneOnco's Chairman of the Board, Chief Executive Officer, Chief Scientific Officer and Executive Director; Rex Yeung, Chairman of the Audit Committee; and Juno Chong, Senior Financial Manager; (bottom photo from left) Bobo Leung; Joe Yang, A&A manager; Shelley Zhao, assistant A&A manager, Yuki Luo, A&A associate, and Bobby Yu.
About the client
Founded in June 2015 in the Chinese Mainland, ImmuneOnco is a clinical-stage biotechnology company dedicated to the development of immuno-oncology therapies. ImmuneOnco’s pipeline consists of 14 drug candidates featuring a comprehensive innate-immunity-based asset portfolio targeting CD47 and other novel immune checkpoints, with eight ongoing clinical programs.
Source: ImmuneOnco's IPO prospectus published on 24 August 2023
About this IPO engagement
After the IPO engagement kicked off, Deloitte China promptly established a multi-disciplinary engagement team with members from the Audit & Assurance (A&A), Quality Control (EQCR), Technical, Internal Control, Tax Review, and Valuation Review teams.
Deloitte China served ImmuneOnco throughout its IPO journey with a high-quality philosophy of "diligence and excellence". The engagement team provided consistent professional services at every stage of the IPO process and worked closely with other professional parties to achieve the successful listing of ImmuneOnco in Hong Kong's capital market.
Deloitte China congratulates ImmuneOnco on its successful listing on the SEHK. We will continue to provide high quality professional services to assist more clients to take one-step ahead in today's increasingly competitive and complex business environment.
Stay tuned for more exciting listing news of our clients.
